Insulin Like Growth Factor-1 Against Oxidative Stress in Vitiligo

Vitiligo Clinical Trial

Official title:

Assessing the Protective Role of Insulin Like Growth Factor 1 Against Oxidative Stress in Vitiligo Patients

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05812079
• Other study ID #: IGF-1 in Vitilgo
• Status: Not yet recruiting
• Start date: February 1, 2024
• Est. completion date: October 1, 2024

Study information

• Verified date: February 2024
• Source: Cairo University
• Contact: Marwa El-Mesidy, MD
• Phone: 01005139967
• Email: marwa.elmesidy[@]kasralainy.edu.eg
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Insulin like growth factor has a protective role on melanocytes against the oxidative stress. The aim is to investigate this effect in vitiligo patients.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 33
• Est. completion date: October 1, 2024
• Est. primary completion date: October 1, 2024
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• Non-segmental vitiligo

Exclusion Criteria:

1. Pregnant or lactating females

2. Smokers

3. Patients with any endocrinal disease known to affect GH or IGF-1 as Diabetes (by measuring HbA1c) and Thyroid disturbance (by measuring TSH)

4. Patients with liver disease (by measuring AST, ALT and GGT)

5. Obese patients (by measuring BMI)

6. Patients with history of ischemic heart disease (known medical history of angina or myocardial infarction or history of recurrent chest pain, left shoulder pain, shortness of breath or fatigue on the ordinary effort or less than the ordinary effort )

7. Patients with history of Peripheral arterial disease (Known medical history of peripheral arterial thrombosis or history of recurrent claudications)

8. Patients with history of cerebero-vascular disease (known medical history of transient ischemic attacks or stroke)

9. Patients who received systemic treatment for vitiligo during the previous six months or topical treatment during the previous two months

Related Conditions & MeSH terms

• Vitiligo

Intervention

Diagnostic Test:
• skin biopsy examined by ELISA technique
skin biopsy examined by ELISA technique

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Cairo University

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Investigate for IGF-1 and IMA levels in vitiligo	To measure the level of IGF-1 and the level of IMA in perilesional and distant skin of vitiligo patients and compare these levels with normal controls to investigate the relationship between IGF-1, as a protective from oxidative stress and IMA, as a marker of oxidative stress in vitiligo.	one year
Secondary	Measure IMA in vitiligo and correlate it with psychological status of patients	To measure the serum level of IMA as a marker of oxidative stress in vitiligo patients versus normal controls 2- To correlate the findings with the VIS-22 score	One year